Management guidelines for heart transplant candidates released Guideline 02 February 2013 Pages: 2 - 2
Guidelines for the use of fluoroquinolones in children have been released by the American Academy of Pediatrics (AAP) Committee on Infectious Diseases. Guideline 02 February 2013 Pages: 2 - 2
Support for inhospital aspirin and β-blocker use varies in the US Clinical study 02 February 2013 Pages: 3 - 3
Bristol-Myers Squibb's entecavir [Baraclude] has been approved by the Scottish Medicines Consortium (SMC) as a treatment for chronic hepatitis B virus (HBV) infection, News item 02 February 2013 Pages: 3 - 3
Patients in the US are being advised to delay starting treatment with Roche's ibandronic acid [Boniva], News item 02 February 2013 Pages: 3 - 3
Following the 2004 withdrawal of rofecoxib [Vioxx], an initial increase in the prescribing of celecoxib was observed Clinical study 02 February 2013 Pages: 3 - 3
Even a “sizable increase” in funding for postmarketing safety efforts would have a “relatively small” effect on the investment decisions Clinical study 02 February 2013 Pages: 4 - 4
Levonorgestrel-releasing IUS best bet in uterine haemorrhage Clinical study 02 February 2013 Pages: 5 - 5
Increased awareness of metabolic syndrome in children and adolescents is needed Clinical study 02 February 2013 Pages: 5 - 5
US Medicare beneficiaries with cancer have access to nearly all FDA-approved antineoplastic and hormonal agents as a result of Part D coverage, Clinical study 02 February 2013 Pages: 5 - 5
A substantial number of patients with cluster headache “are still not treated adequately”, Clinical study 02 February 2013 Pages: 8 - 8
Olopatadine least costly in seasonal allergic conjunctivitis? Clinical study 02 February 2013 Pages: 8 - 8
A multiple stenting strategy is “more safe and cost-effective” than hybrid stenting Clinical study 02 February 2013 Pages: 9 - 9
Laparoscopic surgery best long-term bet in stress incontinence Clinical study 02 February 2013 Pages: 10 - 10
The routine use of the Angio-Seal STS device provides clinical and cost benefits compared with conventional femoral haemostasis methods Clinical study 02 February 2013 Pages: 11 - 11
The use of eptacog-α [recombinant factor VIIa] to treat acute intracerebral haemorrhage (ICH) may be highly cost effective in the UK, Clinical study 02 February 2013 Pages: 11 - 11
Adefovir or entecavir: choice depends on willingness to pay Clinical study 02 February 2013 Pages: 11 - 11
A “striking geographic variation” exists in the treatment of acute MI Clinical study 02 February 2013 Pages: 12 - 12
The use of darbepoetin-α to treat anaemia in patients with cancer is associated with lower overall costs compared with epoetin-α and epoetin-β, Clinical study 02 February 2013 Pages: 12 - 12
Despite comparable disease severity, patients with elderly-onset rheumatoid arthritis (EORA) receive less 'aggressive' treatment than those with younger-onset rheumatoid arthritis Clinical study 02 February 2013 Pages: 12 - 12
A high level of osteoporosis therapy initiation and continuation appears to have been achieved by the appointment of an “allied health champion” Clinical study 02 February 2013 Pages: 12 - 12
Caesarean section in labour during a woman's first delivery increases cumulative hospital care costs for subsequent deliveries, Clinical study 02 February 2013 Pages: 13 - 13
Education programme for musculoskeletal disorders a winner Clinical study 02 February 2013 Pages: 13 - 13
Improved QOL with albumin interferon-α fusion protein + ribavirin in hepatitis C Media release 02 February 2013 Pages: 13 - 13
Legislation signed by President George Bush has legalised the importation of drugs from Canada to the US, News item 02 February 2013 Pages: 14 - 14
Under a new California law, manufacturers will be forced to provide discounted drugs to needy patients by 2010 News item 02 February 2013 Pages: 14 - 14
In Germany, the cost of treatment with Acomplia [rimonabant] or Exubera [insulin] will not be reimbursed by the state health insurance, News item 02 February 2013 Pages: 14 - 14
Driven by strong sales in the cancer medicines, the revenues for Roche reached SwF30 billion* in the first 9 months of 2006, News item 02 February 2013 Pages: 14 - 14
Pharmac, New Zealand's drug subsidy agency, has announced that trastuzumab [Herceptin] is to remain unfunded Media release 02 February 2013 Pages: 14 - 14